It would not be an exaggeration to say that Bausch Health (BHC) drew significant attention across the healthcare industry in declaring its intention to cease participation in what it deemed two “optional” Federal drug pricing programs — the Medicaid Drug Rebate Program and the 340B Drug Pricing Program — effective October 1, 2025.

What about Bausch’s commitment to 340B hospitals and their patients?

Continue reading on VytlOne: Bausch Has Pulled Its Drug Catalog From The 340B Program.